Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Gilead Fixes the Price of COVID-19 Drug Remdesivir; the Government Secures the Bulk of Its Supply

Remdesivir, a malaria drug that has been repurposed to treat COVID-19 and currently represents the best hope for attacking the disease, now has a price tag. On Monday, the company behind the


Remdesivir, a malaria drug that has been repurposed to treat COVID-19 and currently represents the best hope for attacking the disease, now has a price tag. On Monday, the company behind the medication, Gilead Sciences (NASDAQ: GILD), said it will be sold at $390 per vial. Therefore, the basic price for a five-day treatment course using six vials would be $2,340.

Gilead added that "[b]ecause of the way the U.S. system is set up and the discounts that government healthcare programs expect," the price for U.S. private insurance companies will be $520 per vial. This equates to $3,120 per treatment course, with the patient's final bill depending on the policy's coverage.

Image source: Gilead Sciences.

Continue reading


Source Fool.com

Like: 0
Share

Comments

You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more